Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01756729 · ClinicalTrials.gov registry record · Phase 4
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
A Phase 4 study, sponsored by NovoCure.
- Terminated
- Registry status
- Phase 4
- Development phase
- 13
- Enrollment target
NCT01756729: Clinical Trial Phase 4 study, sponsored by NovoCure.
NCT01756729 is a Phase 4 study that was terminated before completion, run by NovoCure. The registered enrollment target is 13 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01756729, a Phase 4 study, was terminated before completion, sponsored by NovoCure.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a non-randomized, concurrent control study, designed to confirm that the efficacy of the NovoTTF-100A System in patients with recurrent GBM treated in a real life settings following approval is comparable to that of BSC chemotherapy patients. The device is a portable, battery operated device that was approved for the treatment of adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM), following histologically- or radiologically-confirmed recurrence in the supra-tentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.
Interventions
- DEVICE NovoTTF-100A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2012-12 |
| Est. Completion | 2018-01 |
| Phase | Phase 4 |
Why NCT01756729 stopped before completion
NCT01756729 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which NovoTTF-100A is the first listed.
NCT01756729 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01756729 about?
NCT01756729 is a clinical study titled "Post-approval Study of NovoTTF-100A in Recurrent GBM Patients". This is a non-randomized, concurrent control study, designed to confirm that the efficacy of the NovoTTF-100A System in patients with recurrent GBM treated in a real life settings following approval is comparable to that of BSC chemotherapy patients. The device is a portable, battery operated device...
What is the current status of trial NCT01756729?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 13 participants. The study started on 2012-12. Estimated completion is 2018-01.
What interventions are being tested in trial NCT01756729?
The interventions under investigation include: NovoTTF-100A (DEVICE).
Who is sponsoring clinical trial NCT01756729?
This trial is sponsored by NovoCure, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01756729's enrollment target sits among peer trials
13 1910th of 2000 higher than 88 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia